Evidence map›Paper›PMID 33519770›Full record

ArticleFrontiers in microbiology2020

Inactivation Effect of Violet and Blue Light on ESKAPE Pathogens and Closely Related Non-pathogenic Bacterial Species - A Promising Tool Against Antibiotic-Sensitive and Antibiotic-Resistant Microorganisms.

Katharina Hoenes, Richard Bauer, Tobias Meurle, Barbara Spellerberg, Martin Hessling

Open access · goldAbstract read
In one paragraph

Article in Frontiers in microbiology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
25citing papers in PubMed, 2 pooled it
5.6field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

25 citing papers in PubMed, 2 syntheses or guidelines pooled it, 56 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Article
  4. Article
  5. Article
  6. Review
  7. Article
  8. Article
  9. Review
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 2 institutions in 1 country.

Katharina HoenesInstitute of Medical Engineering and Mechatronics, Ulm University of Applied Sciences, Ulm, Germany.
Richard BauerInstitute of Medical Microbiology and Hygiene, University Hospital Ulm, Ulm, Germany.
Tobias MeurleInstitute of Medical Engineering and Mechatronics, Ulm University of Applied Sciences, Ulm, Germany.
Barbara SpellerbergInstitute of Medical Microbiology and Hygiene, University Hospital Ulm, Ulm, Germany.
Martin HesslingInstitute of Medical Engineering and Mechatronics, Ulm University of Applied Sciences, Ulm, Germany.
Technische Hochschule Ulm · DEUniversity Hospital Ulm · DE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Due to the globally observed increase in antibiotic resistance of bacterial pathogens and the simultaneous decline in new antibiotic developments, the need for alternative inactivation approaches is growing. This is especially true for the treatment of infections with the problematic ESKAPE pathogens, which include

Indexed as

405 nm450 nmantimicrobial blue lightESKAPE pathogensnon-pathogenphotoinactivationvisible light irradiation

Identifiers

PMID33519770
PMCPMC7838345
OpenAlexW3118389816

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.